Is Olema Pharmaceuticals, Inc. (OLMA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 25.1% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 25.1% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 0.3% / 33% | 96.3% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 25.1% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 0.3% / 33% | 96.3% / 33% | 0.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -36.6% | |
| Return on Assets (ROA) | -21.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$147M |
| Free Cash Flow | -$147M |
| Total Debt | $4M |
| Debt-to-Equity | 0.9 |
| Current Ratio | 9.9 |
| Total Assets | $533M |
Price & Trading
| Last Close | $14.12 |
| 50-Day MA | $21.76 |
| 200-Day MA | $14.54 |
| Avg Volume | 1.7M |
| Beta | 2.0 |
|
52-Week Range
$2.86
| |
About Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Olema Pharmaceuticals, Inc. (OLMA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Olema Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Olema Pharmaceuticals, Inc.'s debt ratio?
Olema Pharmaceuticals, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.3%.
What are Olema Pharmaceuticals, Inc.'s key financial metrics?
Olema Pharmaceuticals, Inc. has a market capitalization of $1.2B. Return on equity stands at -36.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.